Nikhil I. Khushalani

Jul 2, 2024 | onclive.com | Nikhil I. Khushalani

CommentaryVideoJuly 2, 2024Author(s):Nikhil Khushalani, MD, discusses the benefits and limitations of fixed-dose treatment regimens in patients with unresectable or metastatic melanoma.

Mar 1, 2024 | jitc.bmj.com | Nikhil I. Khushalani |Patrick A. Ott |Robert Ferris |Tina Cascone

DiscussionWe report here data from two phase 1/2 trials that aimed to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary efficacy of novel combinations of urelumab with cetuximab (CA186-018) or nivolumab (CA186-107). The combination of urelumab-0.1 or urelumab-8 with cetuximab-240 was well tolerated and did not appear to have additive toxicity profiles beyond the expected safety profile of cetuximab.

Mar 15, 2023 | onclive.com | Nikhil I. Khushalani |Martin F. Dietrich |Jason Luke |Vishal Patel

OncologyLiveOncology FellowsSupplements And Featured PublicationsAll Publications